Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for ...

Consensus $79.24M. The company said, “Preliminary unaudited revenue for the full year ended December 31, 2024 is expected to be between $79.4 ...

Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace ...

CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

PURPOSE To determine the characteristics that permit diagnosis of the type of epilepsy beginning in the 1st year of life, and to determine from what age such characteristics are recognisable. PATIENTS ...

According to the FDA, 1 each of the unapproved products were sold on the firm’s websites, Amazon shops, and social media ...

Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...

The brains of people with epilepsy have additional features to their dynamic repertoire, particularly the paroxysmal occurrence of seizures. Substantial effort over decades has produced a detailed ...

A risk factor is something that makes a person more likely to develop seizures and epilepsy. Sometimes a risk factor can cause scarring of the brain or lead to areas of the brain not developing or ...